Volume 30, Number 12—December 2024
Research
Human Circovirus in Patients with Hepatitis, Hong Kong
Figure 6

Figure 6. Cell-binding assay showing binding of HCirV VLPs to PLC/PRF/5 cells in study of HCirV in patients with hepatitis. HEV VLPs (bHEV p239) is included as a positive control; SARS-CoV-2 NP protein is included as a negative control. Nuclei are counterstained with DAPI. Cap, capsid; HCirV, human circovirus; HEV, hepatitis E virus; NP, nucleoprotein; VLP, virus-like particle.
1These authors contributed equally to this article.
Page created: October 04, 2024
Page updated: November 26, 2024
Page reviewed: November 26, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.